This is a working overview of peptidase, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-03. Anything still debated is marked as such rather than presented as settled.
Dry powder is normally held at -20 degrees Celsius or lower, in a sealed container with desiccant and protection from light. Reconstituted solutions are usually kept at 2 to 8 degrees Celsius for short periods and frozen for longer ones. Proline residues at several positions are generally associated with some resistance to peptidase attack, but chemical stability still declines at neutral to alkaline pH and at elevated temperature. Exact shelf-life figures are product-specific and are not standardised across suppliers.
Identity and purity are usually assessed by reversed-phase high-performance liquid chromatography, with mass spectrometry used to confirm molecular mass and sequence information. Amino acid analysis and peptide mapping may supplement these methods. Certified reference standards are scarce, and many commercial lots are sold as research chemicals without a pharmacopoeial monograph. Regulatory treatment differs by country: Selank is a registered prescription medicine in Russia, while in the European Union and the United States it is not an approved drug and may fall under research-chemical or unapproved-product frameworks.
Enzymatic stability motivates the extra three residues at the carboxyl end. Native tuftsin is cleaved quickly by circulating aminopeptidases and carboxypeptidases, which limits its duration of action and its usefulness as a tool compound. Extending the chain with proline-rich segments is a common design tactic because proline constrains the backbone and slows proteolysis. The same Pro-Gly-Pro motif appears in other Russian-developed peptides of the era. Whether the full seven-residue chain is required for activity, or whether it acts mainly as a prodrug releasing tuftsin, remains unresolved.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. Its four N-terminal residues reproduce tuftsin, a tetrapeptide fragment of the immunoglobulin heavy chain, while the C-terminal Pro-Gly-Pro extension is a synthetic addition. The peptide has a molecular mass near 752 daltons and carries a net positive charge at physiological pH because of the arginine and lysine side chains. Published indexes list it under the name Selank and the sequence abbreviation TKPRPGP. Solid-phase peptide synthesis is the standard production route for research quantities.
Development took place at the Institute of Molecular Genetics of the Russian Academy of Sciences, where a series of short peptides were designed in the 1980s and 1990s. Selank was selected from variants of tuftsin that showed resistance to plasma peptidases. Russian regulatory approval covers it as an anxiolytic agent given intranasally. Outside that market the compound is normally handled as a research chemical rather than a medicine, and no widely recognised international pharmacopoeial monograph exists. The name Selank is a coined trade designation rather than a systematic chemical name.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Lyophilised solid form |
| Solubility class | Freely soluble in water | Hydrophilic heptapeptide |
| Dry storage temperature | -20 degrees Celsius or lower | Sealed, desiccated, protected from light |
| Solution storage | 2 to 8 degrees Celsius short term | Avoid repeated freeze-thaw cycles |
| Common identification method | Reversed-phase HPLC with mass spectrometry | Confirms purity and molecular mass |
Pharmacokinetic data are sparse and largely derived from animal work. After intranasal administration the peptide appears in plasma within minutes, and reported half-lives are short, on the order of minutes to tens of minutes. Degradation proceeds through ordinary proteolytic cleavage into constituent amino acids and smaller fragments. Direct evidence that intact Selank reaches brain tissue in meaningful amounts is limited, and the extent of blood-brain barrier penetration is debated. Some authors argue that fragments, not the parent peptide, carry much of the observed activity.
Published clinical work is concentrated in Russian-language journals and generally involves small samples without independent replication. Systematic reviews in English note the shortage of randomised, placebo-controlled trials and the difficulty of verifying methods from translated reports. Outcome measures vary between studies, which complicates pooling of results. Interest in the compound as a cognitive or anxiolytic agent therefore rests on a thinner evidence base than the volume of citations suggests. Replication in well-powered trials with preregistered endpoints would be needed before firm conclusions about efficacy can be drawn.
Selank is a synthetic heptapeptide with the sequence Thr-Lys-Pro-Arg-Pro-Gly-Pro. It was designed as a stabilized analogue of tuftsin, a naturally occurring tetrapeptide fragment derived from the immunoglobulin heavy chain. The additional Pro-Gly-Pro segment at the carboxyl terminus is intended to slow enzymatic cleavage. The compound is usually described in the literature as a synthetic peptide with anxiolytic and cognitive-related activity, a label that reflects a research context rather than an approved therapeutic category.
Most published work on selank originates from a small number of research groups in the Russian Federation. A large share of that record appears in Russian-language journals, which limits access for readers who rely on English-indexed databases. Independent replication by laboratories outside the original research network is sparse in publicly available sources. This concentration of origin and language is a frequently noted feature when the compound is summarized in broader reviews of synthetic peptides.
== Research == (R)-MDMA is under development separately by AtaiBeckley, Empath Biosciences (EmpathBio) and Definium Therapeutics (formerly MindMed). It is being developed by AtaiBeckley for social anxiety disorder, by Empath Biosciences for the treatment of PTSD and social phobia and it is being developed by Definium Therapeutics for the treatment of PDDs or autism. As of February 2026, the drug is in phase 2 clinical trials for social phobia and autistic spectrum disorders, whereas no recent development has been reported for PTSD. The results of AtaiBeckley's phase 2a trial for treatment of social phobia have been released, with the drug showing moderate effectiveness and a generally favorable safety profile for this indication.
== Side effects == Methyldopa is capable of inducing a number of adverse side effects, which range from mild to severe. Nevertheless, they are generally mild when the dose is less than 1 gram per day. Side effects may include:
==== Hydroxyurea ==== Hydroxyurea is another drug that can sometimes be administered to relieve anemia caused by beta-thalassemia. This is achieved, in part, by reactivating fetal haemoglobin production; however its effectiveness is uncertain.
Bicalutamide is eliminated in similar proportions in feces (43%) and urine (34%), while its metabolites are eliminated roughly equally in urine and bile. The drug is excreted to a substantial extent in unmetabolized form, and both bicalutamide and its metabolites are eliminated mainly as glucuronide conjugates. The glucuronide conjugates of bicalutamide and its metabolites are eliminated from the circulation rapidly, unlike unconjugated bicalutamide. The pharmacokinetics of bicalutamide are not affected by consumption of food, a person's age or body weight, renal impairment, or mild-to-moderate hepatic impairment. However, steady-state levels of bicalutamide are higher in Japanese individuals than in white people.
==== Early domestic and foreign policy ==== In an effort to reduce overcrowding, on 15 December Noboa proposed deporting 1,500 foreign prisoners who are incarcerated in Ecuador. He also said he would consider constructing two maximum security prisons, drawing inspiration from El Salvador. The same day, Noboa announced he would seek to cut $1 billion in government spending while raising revenue via gold reserves worth around $300 million. Noboa addressed the UN Security Council On 9 December, highlighting criminal gang activities and overall security as high priorities. On 10 December 2023, Noboa attended the inauguration of Argentinian President Javier Milei. Noboa also met with Ukrainian President Volodymyr Zelenskyy, who praised him for his stance on Russia's invasion. The two discussed expanding bilateral relations, primarily surrounding security and trade. Zelenskyy also invited Noboa to visit Ukraine.
Sources: en.wikipedia.org
Dr. George D. Winter (1927–1981) was the British-born pioneer of moist wound healing. In 1962, while working at the Department of Biomechanics and Surgical Materials at the University of London, Winter published his landmark Nature paper Formation of the scab and the rate of epithelisation of superficial wounds in the skin of the young domestic pig (Nature 193:293 1962) where he demonstrated that, contrary to the conventional wisdom that wounds should be allowed to dry out and form scabs to promote healing, wounds instead healed faster if kept moist. Winter formed multiple partial thickness wounds on the backs of pigs, half left open to the air and half covered with a polymer film to keep them hydrated. The latter wounds healed faster, as measured by the migration of new epithelium on the wound bed. This work began the evolution of modern wound dressings that promote moist wound healing. George D. Winter was the first president of the European Society for Biomaterials and has an annual award named after him.
The condensation of N-(2-fluoro-6-(trifluoromethyl)benzyl)urea [830346-46-8] (1) with t-butyl acetoacetate [1694-31-1] under acidic conditions to generate the 6-methyluracil derivative, [830346-47-9] (2). Halogenation using iodine monochloride provided [1150560-54-5] (3). Suzuki coupling with 2-fluoro-3-methoxyphenylboronic acid [352303-67-4] (4) gave [1150560-59-0] (5). The catalyst used for this step was PdCl2(dtbpf). FGI of N-Boc-2-phenyl-D-glycinol [102089-74-7] (6) to the mesylate, [102089-75-8] (7) was followed by alkylation and alkaloine hydrolysis of the Boc protecting group to give [830346-50-4] (8). Alkylation of the primary amine with ethyl 4-bromobutyrate [2969-81-5] (9) gave ester [832720-84-0] (10). Saponification of the ester in alcoholic lye completed the synthesis of elagolix sodium (11).
Lancashire Police confirm the body found in the River Wyre the previous day is that of Nicola Bulley. 21 February – A planned 48-hour strike by nurses is called off to allow the Royal College of Nursing and Department of Health and Social Care to enter into renewed negotiations. The BMA maintains that junior doctor's pay has been cut by 26% since 2008 after inflation is considered. The UK Government recommends a 3.5% pay rise for public sector workers in England, below the rate of inflation. 22 February – Following a trial at Winchester Crown Court, Shaye Grove, 27, a woman obsessed with serial killers, is sentenced to life imprisonment with a minimum of 23 years for the murder of her boyfriend, who she stabbed to death in July 2022. 23 February – Figures produced by the Office for National Statistics show school absences in England remain above their pre-COVID levels, with 25.1% of pupils regularly absent during the autumn term of 2022 compared to 13.1% in autumn 2019. 24 February – The British Medical Association announces that junior doctors in England will begin a three-day strike on 13 March.
Downstream processing refers to the recovery and the purification of biosynthetic products, particularly pharmaceuticals, from natural sources such as animal tissue, plant tissue or fermentation broth, including the recycling of salvageable components as well as the proper treatment and disposal of waste. It is an essential step in the manufacture of pharmaceuticals such as antibiotics, hormones (e.g. insulin and human growth hormone), antibodies (e.g. infliximab and abciximab) and vaccines; antibodies and enzymes used in diagnostics; industrial enzymes; and natural fragrance and flavor compounds. Downstream processing is usually considered a specialized field in biochemical engineering, which is itself a specialization within chemical engineering. Many of the key technologies were developed by chemists and biologists for laboratory-scale separation of biological and synthetic products, whilst the role of biochemical and chemical engineers is to develop the technologies towards larger production capacities. Downstream processing and analytical bioseparation both refer to the separation or purification of biological products, but at different scales of operation and for different purposes. Downstream processing implies manufacture of a purified product fit for a specific use, generally in marketable quantities, while analytical bioseparation refers to purification for the sole purpose of measuring a component or components of a mixture, and may deal with sample sizes as small as a single cell.
Sources: en.wikipedia.org
Dry powder is normally held at -20 degrees Celsius or below in a sealed, light-protected container with desiccant. Brief room-temperature handling during weighing is generally tolerated. Storage instructions vary between suppliers, so the accompanying certificate of analysis should be followed.
Reversed-phase HPLC establishes purity, while mass spectrometry confirms the expected molecular mass. Sequence confirmation may use tandem mass spectrometry or peptide mapping. A certificate of analysis typically reports these results alongside the analytical method applied.
In Russia it is a registered medicine available by prescription. In many other countries it is not approved for human use and is supplied only as a research chemical. Import and possession rules differ by jurisdiction, and buyers are responsible for checking local requirements.
Selank is a seven-amino-acid peptide built from the tuftsin sequence plus a Pro-Gly-Pro tail. It is produced by chemical synthesis rather than extracted from a natural source. The free peptide is usually supplied as a lyophilised powder or in an aqueous formulation.